Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA,a multiethnic US cohort (LUMINA XL)

Abstract

Get full access to this article

View all access options for this article.

References

The Canadian Hydroxychloroquine Study Group . A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus . N Engl J Med 1991; 324: 150–154 .

Tsakonas E , Joseph L , Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus . Lupus 1998; 7: 80–85 .

Fessler BJ , Alarcón GS , McGwin G Jr et al. Systemic lupus erythematosus in a multiethnic group: XVI. Hydroxychloroquine usage is associated with a lower risk of damage accrual . Arthritis Rheum 2005; 52: 1473–1480 .

Ruiz-Irastorza G , Egurbide MV , Ibarra S et al. Effect of antimalarials on long-term survival of patients with systemic lupus erythematosus . Lupus 2005; 14: 220-220 .

Alarcón GS , McGwin G, Jr Fessler BJ et al. “Confounding by indications” partially explains the protective effect of hydroxychloroquine (HCQ) in SLE survival: data from a multiethnic US cohort . Arthritis Rheum 2005; 52: S726-S726 .

Morand EF , McCloud PI , Littlejohn GO . Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis . Ann Rheum Dis 1992; 51: 1318–1321 .

Wang C , Fortin PR , Li Y , Panaritis T , Gans M , Esdaile JM . Discontinuation of antimalarial drugs in systemic lupus erythematosus . J Rheumatol 1999; 26: 808–815 .

Petri M . Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis . Lupus 1996; 1: S16–S22 .

Molad Y , Gorshtein A , Wysenbeek AJ et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort . Lupus 2002; 11: 356–361 .

10.

Rahman P , Gladman DD , Urowitz MB , Yuen K , Hallett D , Bruce IN . The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs . J Rheumatol 1999; 26: 325–330 .

11.

Hodis HN , Quismorio FP , Wickham E , Blankenhorn DH . The lipid, lipoprotein, and apolipoprotien effects of hydroxychloroquine inpatients with systemic lupus erythematosus . J Rheumatol 1993; 20: 661–665 .

12.

Wallace DJ , Metzger AL , Stecher VJ , Turnbull BA , Kern PA . Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids . Am J Med 1990; 89: 322–326 .

13.

Gerstein HC , Thorpe KE , Taylor DW , Haynes RB . The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas–a randomized trial . Diabetes Res Clin Pract 2002; 55: 209–219 .

14.

Emami J , Gerstein HC , Pasutto FM , Jamali F . Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent . Can J Physiol Pharmacol 1999; 77: 118–123 .

15.

Quatraro A , Consoli G , Magno M et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med 1990; 112: 678–681 .

16.

Chrisman OD , Snook GA , Wilson TC , Short JY . Prevention of venous thromboembolism by administration of hydroxychloroquine. A preliminary report . J Bone Joint Surg Am 1976; 58: 918–920 .

17.

Pilcher DB . Hydroxychloroquine sulfate in prevention of thromboembolic phenomena in surgical patients . Am Surg 1975; 41: 761–766 .